MedTrace Logo

The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism

NCT02262026 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2023-02-24

No results posted yet for this study

Summary

Functional neuroimaging of alcoholism vulnerability: glutamate, reward, impulsivity, and Pavlovian-to-instrumental transfer (PIT), part II Saracatinib

Conditions

  • Alcoholism

Interventions

DRUG

125 mg AZD0530

Randomized to receive 125 mg of AZD0530

DRUG

50 mg AZD0530

Randomized to receive 50 mg of AZD0530

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Godfrey D Pearlson, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-01
Primary Completion
2019-04-26
Completion
2019-04-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02262026 on ClinicalTrials.gov